Apr 10, 2021
|
HENDERSON, Nev. --(BUSINESS WIRE)--Apr. 10, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today presented a data update on the safety and tolerability of twice daily (BID) administered poziotinib in NSCLC patients
|
|
Apr 05, 2021
|
HENDERSON, Nev. --(BUSINESS WIRE)--Apr. 5, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a poster presentation on safety and tolerability of twice daily administered poziotinib in patients with EGFR or
|
|
Mar 30, 2021
|
Poziotinib receives Fast Track Designation from FDA Preliminary safety and efficacy data for poziotinib twice daily dosing (BID) demonstrates improved anti-tumor activity and reduced toxicity relative to once daily dosing FDA has scheduled the pre-approval inspection at the ROLONTIS ®
|
|
Mar 26, 2021
|
HENDERSON, Nev. --(BUSINESS WIRE)--Mar. 26, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the fourth quarter and full year 2020 financial results and provide a
|
|
Mar 16, 2021
|
HENDERSON, Nev. --(BUSINESS WIRE)--Mar. 16, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) has scheduled the pre-approval inspection at the ROLONTIS®
|
|
Mar 11, 2021
|
HENDERSON, Nev. --(BUSINESS WIRE)--Mar. 11, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for poziotinib for the
|
|
Mar 02, 2021
|
HENDERSON, Nev. --(BUSINESS WIRE)--Mar. 2, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today presented results from Cohort 3 and initial twice daily (BID) dosing safety and efficacy data for poziotinib from Cohort 5
|
|
Feb 26, 2021
|
HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 26, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a poster presentation on interim safety evaluation of same-day dosing of ROLONTIS ® (eflapegrastim) in patients
|
|
Feb 23, 2021
|
HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 23, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced two presentations, one oral and one eposter, at the upcoming European Society for Medical Oncology Targeted
|
|
Feb 04, 2021
|
HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 4, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Oncology Day.
|
|
Jan 22, 2021
|
HENDERSON, Nev. --(BUSINESS WIRE)--Jan. 22, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced an oral presentation on updated efficacy, safety, and dosing management of poziotinib from Cohorts 1 and 2 of
|
|
Jan 05, 2021
|
HENDERSON, Nev. --(BUSINESS WIRE)--Jan. 5, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will provide an overview of the company's business strategy and development-stage programs at
|
|
Dec 22, 2020
|
FDA agrees to the submission of an NDA for poziotinib for non-small cell lung cancer (NSCLC) in previously treated patients with HER2 exon 20 insertion mutations, NDA submission planned for 2021 Cohort 3 of the ZENITH20 clinical trial, which enrolled first-line NSCLC patients with EGFR exon 20
|
|
Dec 14, 2020
|
HENDERSON, Nev. --(BUSINESS WIRE)--Dec. 14, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Nora Brennan to its Board of Directors. Ms. Brennan fills a vacancy left by Ms.
|
|
Dec 04, 2020
|
HENDERSON, Nev. --(BUSINESS WIRE)--Dec. 4, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that three posters highlighting its drug development pipeline would be presented at the upcoming San Antonio
|
|
Nov 09, 2020
|
HENDERSON, Nev. --(BUSINESS WIRE)--Nov. 9, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will present an overview of the company's business strategy and development-stage programs at
|
|
Nov 04, 2020
|
FDA deferred action on the BLA for ROLONTIS ® (eflapegrastim) due to inability to conduct inspection of the manufacturing facility citing COVID-19 related travel restrictions Pre-NDA meeting with FDA is scheduled for poziotinib in NSCLC HER2 exon-20 insertion mutations in previously treated
|
|
Oct 28, 2020
|
HENDERSON, Nev. --(BUSINESS WIRE)--Oct. 28, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the third quarter 2020 financial results and provide a corporate
|
|
Oct 26, 2020
|
Agency cites inability to conduct inspection of the drug substance manufacturing facility due to COVID-19 related travel restrictions HENDERSON, Nev. --(BUSINESS WIRE)--Oct. 26, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology
|
|
Sep 18, 2020
|
HENDERSON, Nev. --(BUSINESS WIRE)--Sep. 18, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today presented additional results from its pivotal Phase 2 clinical trial, ZENITH20, evaluating poziotinib in previously
|
|